Geriatric psychiatry

Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease

Retrieved on: 
måndag, mars 18, 2024
Research, FDA, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Week, Psychosis, Agitation, Commercialization, Medication, Psychiatry, Caregiver, Patient, Geriatric psychiatry, Overalls, MD, Lundbeck, NPI, CMAI, Neuropsychiatry, Safety, Poster, Behavioral neuroscience, Multimedia, Dementia, Annual general meeting, Food

One poster utilized the Neuropsychiatric Inventory (NPI) to explore the relationship of REXULTI on neuropsychiatric symptoms relating to agitation and occupational disruptiveness/caregiver distress related to patients’ behavior.

Key Points: 
  • One poster utilized the Neuropsychiatric Inventory (NPI) to explore the relationship of REXULTI on neuropsychiatric symptoms relating to agitation and occupational disruptiveness/caregiver distress related to patients’ behavior.
  • The NPI, which is administered through a structured caregiver interview, is comprised of 12 domains of neuropsychiatric symptoms including agitation/aggression, irritability/lability, and disinhibition.
  • The analysis demonstrated that REXULTI was associated with reductions in overall neuropsychiatric symptoms and in agitation symptoms (as captured by the NPI) compared with placebo over 12 weeks.
  • “The breadth of data presented at AAGP represents our continued commitment to understanding the full potential of REXULTI on agitation associated with dementia due to Alzheimer’s disease.”

New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older

Retrieved on: 
fredag, mars 15, 2024
Science, Other Science, Biotechnology, Pharmaceutical, Oncology, Health, Mental Health, Genetics, Diagnosis, Depression, Gene, Schizophrenia, Post-traumatic stress disorder, Patient, Research, Bipolar disorder, Anxiety, Personality disorder, Polypharmacy, Pain, Geriatric psychiatry, Annual general meeting, Pharmaceutical industry

The data will be shared via a poster presentation at the 2024 American Association for Geriatric Psychiatry (AAGP) Annual Meeting, taking place March 15-18 in Atlanta.

Key Points: 
  • The data will be shared via a poster presentation at the 2024 American Association for Geriatric Psychiatry (AAGP) Annual Meeting, taking place March 15-18 in Atlanta.
  • “This study found that, despite all patients carrying potentially clinically significant genetic variants, one-third of medication recommendations were due to drug-drug interactions and lifestyle factors provided on the IDgenetix report.
  • Additionally, 58% of the patients in the study were on five or more medications, with an average of seven, at the time of testing.
  • All patients in the study had genetic polymorphisms that could impact medication selection in at least three of the 15 genes on the IDgenetix report.

The Inner Circle acknowledges Mark J. Mills, JD, MD as a Life Achiever 2023-2024

Retrieved on: 
måndag, mars 11, 2024
Harvard Law School, Geriatric psychiatry, Harvard Medical School, University, Philosophy, American Psychiatric Association, Forensic psychiatry, Private practice, New York Medical College, Distinguishing, Columbia University, Distinguished Service Award, Law, MD, American College, Society, Absence, Stanford University, Multimedia, Inner circle, JD, Bronze medal

RALEIGH, N.C., March 11, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Mark J.

Key Points: 
  • RALEIGH, N.C., March 11, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Mark J.
  • Mills, JD, MD is acknowledged as a Life Achiever 2023-2024 for his contributions as a Forensic Psychiatrist.
  • Mills, a highly accomplished forensic psychiatrist, is marking an impressive 48 years of dedication and expertise in the field of forensic psychiatry.
  • As a renowned figure in the industry, Dr. Mills has made substantial contributions to academia and has maintained a thriving private firm, Mark J.

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
onsdag, mars 6, 2024
Senior, Research, SAB, Lecanemab, Clinical Chemistry (journal), Neuroimaging, Lund University, University, Associate, Henrik, Key, School, OGA, Principal, Research and development, Queen Silvia of Sweden, Young, Brain, Therapy, Pharmacology, SAN, UCL, Geriatric psychiatry, Eric, Biomarker, Yale School of Medicine, ACTC, Sahlgrenska University Hospital, University College London, Division, Neurochemistry, FDA, Public health, Phase II, Neurology, Senior advisor, Executive Committee, Patient, Cognition, Yale school, European Grand Prix, Biogen, Pharmaceutical industry

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Retrieved on: 
onsdag, mars 6, 2024
Senior, Research, SAB, Lecanemab, Clinical Chemistry (journal), Neuroimaging, Lund University, University, Associate, Henrik, Key, School, OGA, Principal, Research and development, Queen Silvia of Sweden, Young, Brain, Therapy, Pharmacology, SAN, UCL, Geriatric psychiatry, Eric, Biomarker, Yale School of Medicine, ACTC, Sahlgrenska University Hospital, University College London, Division, Neurochemistry, FDA, Public health, Phase II, Neurology, Senior advisor, Executive Committee, Patient, Cognition, Yale school, European Grand Prix, Biogen, Pharmaceutical industry

LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).

Key Points: 
  • LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ -- Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces the appointments of neurodegenerative disease experts to its Scientific Advisory Board (SAB).
  • Asceneuron is advancing development of its lead asset ASN51 into Phase II clinical development targeting Alzheimer's disease.
  • The Scientific Advisory Board members have vast experience in clinical trial design and biomarkers and will help support this promising program through Phase II clinical development.
  • I am honored to have these stellar neurodegenerative experts join our SAB at a fundamental time of development.

Synergy: Mental Health & Wellness Integrated Expands Services and Opens New Location in Glendale

Retrieved on: 
onsdag, februari 7, 2024
Mental health, MD, Patient, Primary care, Wellness, Medicine, Geriatric psychiatry, TMS, Synergy, Weight management, Commerce, Suite, Face, Medicare, Nursing

SCOTTSDALE, Ariz., Feb. 7, 2024 /PRNewswire/ -- Scottsdale Mental Health & Wellness Institute proudly announces its rebranding as Synergy: Mental Health & Wellness Integrated (SMHWI), reflecting its expanded range of services and geographic footprint. This evolution aligns with the company's commitment to providing comprehensive outpatient mental and physical healthcare services that support the complete wellness of each unique individual, as the practice expands across Arizona and soon to additional states.

Key Points: 
  • Formerly known as Scottsdale Mental Health & Wellness Institute, Synergy: Mental Health & Wellness Integrated is a premier provider of quality outpatient mental and physical health care services expanding across the state of Arizona and beyond.
  • SCOTTSDALE, Ariz., Feb. 7, 2024 /PRNewswire/ -- Scottsdale Mental Health & Wellness Institute proudly announces its rebranding as Synergy: Mental Health & Wellness Integrated (SMHWI), reflecting its expanded range of services and geographic footprint.
  • "Our decision to rebrand as Synergy: Mental Health and Wellness Integrated is a reflection of our commitment to providing comprehensive and integrated mental health care," said Dr. Roland Segal , SMHWI CEO/Founder.
  • Synergy: Mental Health & Wellness Integrated is part of the Turnwell Mental Health Network , a clinician-led, integrated mental health group specializing in local and affordable care for individuals suffering from mental health disorders with a mission to expand access to high-quality care in underserved markets.

Talkiatry Launches Geriatric Psychiatry Services to Support Aging Population

Retrieved on: 
tisdag, januari 30, 2024
Cigna, Life, Amnesia, Ageing, Patient, Friends, Loss, Entrepreneurship, Depression, Mental disorder, Mental health, Geriatric psychiatry, Health, Insurance, Medicare, Nursing

Talkiatry is committed to providing greater access to quality, specialized care for the often-overlooked aging patient population through its easy-to-navigate telehealth platform and team of board-certified geriatric psychiatrists.

Key Points: 
  • Talkiatry is committed to providing greater access to quality, specialized care for the often-overlooked aging patient population through its easy-to-navigate telehealth platform and team of board-certified geriatric psychiatrists.
  • "Geriatric care, especially geriatric psychiatry, needs to be both specific and broad, as there are so many ways a person can age.
  • Talkiatry's geriatric psychiatry services cater and attend to all aging patients," said Georgia Gaveras, DO, co-founder and Chief Medical Officer, Talkiatry.
  • For the geriatric patient population, initial appointments are extended from 60 to 75 minutes, allowing more time for psychiatrists to establish rapport.

BrainCheck Appoints Aaron Greenstein, MD to Clinical Advisory Board

Retrieved on: 
måndag, januari 8, 2024
Report, Dementia, Caregiver, The Wall Street Journal, Research, McLean Hospital, Geriatric psychiatry, Massachusetts General Hospital, Ageing, MD, New York Medical College, CO, Human services, Mass, Mass General Brigham, Harvard Review of Psychiatry, Growth, Patient, MGH, News, Policy, Nursing

AUSTIN, Texas, Jan. 8, 2024 /PRNewswire/ -- BrainCheck, Inc. announced the appointment of Aaron Greenstein, MD, a distinguished, board-certified geriatric psychiatrist specializing in geriatric mental illness and dementia, to its clinical advisory board, enhancing the Company's clinical leadership and expertise. Dr. Greenstein, who has worked for some of the most prestigious academic facilities and influential senior healthcare startups, joins the Company as Clinical Advisor following the recent launch of its next-generation platform and 3-minute screening tool, expanding the first end-to-end solution for cognitive care.

Key Points: 
  • AUSTIN, Texas, Jan. 8, 2024 /PRNewswire/ -- BrainCheck, Inc. announced the appointment of Aaron Greenstein, MD, a distinguished, board-certified geriatric psychiatrist specializing in geriatric mental illness and dementia, to its clinical advisory board, enhancing the Company's clinical leadership and expertise.
  • "Dr. Greenstein's expertise will be invaluable as we continue to innovate and strengthen our offerings to better serve healthcare professionals, patients, and caregivers," said Kim Rodriguez, CEO of BrainCheck.
  • "In previous roles, Dr. Greenstein led objective evaluations of available cognitive assessment and care planning tools, and concluded that BrainCheck has the highest clinical utility and efficacy.
  • His research validates the clinical utility of our technology and we look forward to continuing to incorporate his expert acumen as we evolve our solutions and accelerate nationwide adoption."

Noema Pharma Appoints Robert Lasser, M.D., as Chief Medical Officer

Retrieved on: 
onsdag, november 15, 2023
CNS, Medicine, Johnson & Johnson, Psychiatry, Geriatric psychiatry, Dartmouth College, Lasser, DSM-IV codes, Patient, M.B.A, Mental health, Neurodegenerative disease, Binge eating disorder, Novartis, University, CMO, Roche, Noema, Neurology, McLean Hospital, Pharmaceutical industry, Biochemistry

BASEL, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced Robert Lasser, M.D., M.B.A has joined the Company as Chief Medical Officer (CMO).

Key Points: 
  • BASEL, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced Robert Lasser, M.D., M.B.A has joined the Company as Chief Medical Officer (CMO).
  • Lasser brings over 25 years of CNS experience with a successful track record of medical leadership for neuroscience development and commercialization, and I am excited to welcome him to our leadership team,” said Ilise Lombardo, M.D., Chief Executive Officer Noema.
  • Before that, he was the Chief Medical Officer at MedDay Pharma.
  • Working with the dedicated team at Noema to bring novel therapies to those fighting devastating CNS conditions is part of that continuing devotion.”

Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference

Retrieved on: 
tisdag, oktober 24, 2023
Alzheimer's disease, Medical Affairs Bureau, Saint Louis University School of Medicine, Mortality, MD, Coffee, Safety, News, Professor, Conference, Doctor of Philosophy, CNS, Disease, Agitation, Poster, ADA, ACCORD, Division, Geriatric psychiatry, Therapy, NMDA, Patient, Disability, Central nervous system, Pharmaceutical industry

“Agitation is also a significant risk factor for early admission to long term care facilities.

Key Points: 
  • “Agitation is also a significant risk factor for early admission to long term care facilities.
  • The outcome of the ACCORD trial with AXS-05 demonstrating positive efficacy results in agitation associated with Alzheimer's dementia, while being generally well-tolerated, is welcome news."
  • Results of the trial demonstrated rapid and sustained clinical response in patients with ADA during the open-label AXS-05 treatment phase.
  • Details for the presentation are as follows:
    Title: Efficacy and Safety Of AXS-05 in Agitation Associated With Alzheimer’s Disease: Results From ACCORD, a Phase 3, Double-Blind, Placebo-Controlled, Relapse Prevention Trial